Amylyx posts Phase 3 LUCIDITY presentation on avexitide for post-bariatric hypoglycemia

• Amylyx highlighted Phase 3 LUCIDITY topline data for avexitide in post-bariatric hypoglycemia, meeting the primary endpoint and all secondary endpoints.
• Primary endpoint showed a 55% reduction in the composite rate of Level 2 and Level 3 hypoglycemic events versus placebo at Week 16 (p=0.000003).
• Trial enrolled 78 patients in a randomized, double-blind design, testing avexitide 90 mg once daily versus placebo over 16 weeks.
• Safety profile described as generally well tolerated, with no treatment-related serious adverse events; common events included diarrhea and injection-site reactions.
• Company outlined plans for an FDA NDA submission by end-2026, targeting a potential commercial launch in 2027 if cleared.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amylyx Pharmaceuticals Inc. published the original content used to generate this news brief on August 18, 2026, and is solely responsible for the information contained therein.